Alzheimer's disease

Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
BioSpace
Alzheimer's disease
drug development
diagnostics
aducanumab
Biogen
Flag link:
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
Xconomy
Biogen
FDA
aducanumab
Alzheimer's disease
Flag link:
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work
Fierce Biotech
Amylyx Pharmaceuticals
funding
ALS
Alzheimer's disease
Flag link:
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Endpoints
Axsome Therapeutics
Alzheimer's disease
AXS-05
major depressive disorder
Flag link:
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
BioSpace
Denali Therapeutics
Sanofi
DNL747
ALS
Alzheimer's disease
DNL788
clinical trials
Flag link:
Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
Endpoints
Alzheimer's disease
Athira Pharma
clinical trials
Flag link:
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
BioPharma Dive
Eli Lilly
FDA
Alzheimer's disease
R&D
tau tangles
Tauvid
imaging
diagnostics
Flag link:
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Endpoints
Shionogi
Alzheimer's disease
Tetra Therapeutics
M&A
Flag link:
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Endpoints
Acadia Pharma
Vanderbilt
Nuplazid
drug development
Alzheimer's disease
Parkinson's Disease
Flag link:
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout
Fierce Pharma
Biogen
Alzheimer's disease
aducanumab
FDA
drug manufacturing
Flag link:
Has Biogen Found the Answer to Treating Alzheimer's?
Has Biogen Found the Answer to Treating Alzheimer's?
Motley Fool
Biogen
FDA
Alzheimer's disease
aducanumab
Flag link:
Axsome shares rocket up on a surprise win for late-stage Alzheimer’s agitation study — but this is no easy layup
Axsome shares rocket up on a surprise win for late-stage Alzheimer’s agitation study — but this is no easy layup
Endpoints
Axsome Therapeutics
Alzheimer's disease
clinical trials
FDA
AXS-05
Flag link:
FDA clears US trials of Green Valley’s Alzheimer’s drug
FDA clears US trials of Green Valley’s Alzheimer’s drug
Pharmaforum
Green Valley Pharmaceuticals
China
clinical trials
FDA
Alzheimer's disease
Oligomannate
Flag link:
Biogen shares fall as company pushes back Alzheimer’s drug filing
Biogen shares fall as company pushes back Alzheimer’s drug filing
MedCity News
Biogen
earnings
Alzheimer's disease
aducanumab
FDA
Flag link:
Cerevance Nabs $45 Million in Funding to Support CNS Disease Research
Cerevance Nabs $45 Million in Funding to Support CNS Disease Research
BioSpace
Cerevance
CNS
Alzheimer's disease
Parkinson's Disease
Flag link:
Biogen Alzheimer's filing likely hit by pandemic, as drugs against the disease set for delay
Biogen Alzheimer's filing likely hit by pandemic, as drugs against the disease set for delay
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
FDA
pandemic
COVID-19
Flag link:
Alzheimer's researchers link glucose metabolism to disease pathology, uncovering new drug targets
Alzheimer's researchers link glucose metabolism to disease pathology, uncovering new drug targets
Fierce Biotech
R&D
Alzheimer's disease
glucose metabolism
Flag link:
Biogen Sues Company Over Allegedly Selling Knockoff Alzheimer's Treatment
Biogen Sues Company Over Allegedly Selling Knockoff Alzheimer's Treatment
BioSpace
Biogen
patents
Alzheimer's disease
aducanumab
Creative Biolabs
Flag link:
Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study
Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study
BioSpace
Axon Neurosciences
Alzheimer's disease
clinical trials
vaccines
Flag link:
Biogen sues over 'brazenly' copied aducanumab drug
Biogen sues over 'brazenly' copied aducanumab drug
Fierce Biotech
Biogen
Creative Biolabs
Alzheimer's disease
aducanumab
Flag link:

Pages